Biogen Competitors

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Amgen and Biogen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Biogen's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Amgen and Biogen, as provided by MarketBeat.com.

Amgen currently has a consensus target price of $256.0909, suggesting a potential upside of 13.76%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Amgen's stronger consensus rating and higher possible upside, research analysts plainly believe Amgen is more favorable than Biogen.

Volatility and Risk

Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Amgen beats Biogen on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Gilead Sciences and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has lower revenue, but higher earnings than Gilead Sciences. Biogen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Biogen's net margins, return on equity and return on assets.

Volatility and Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Gilead Sciences and Biogen, as provided by MarketBeat.com.

Gilead Sciences currently has a consensus target price of $96.0370, suggesting a potential upside of 55.05%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Gilead Sciences is more favorable than Biogen.

Summary

Biogen beats Gilead Sciences on 8 of the 13 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Vertex Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vertex Pharmaceuticals and Biogen, as provided by MarketBeat.

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, suggesting a potential upside of 37.98%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Biogen.

Summary

Vertex Pharmaceuticals beats Biogen on 10 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Regeneron Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Regeneron Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Regeneron Pharmaceuticals and Biogen, as provided by MarketBeat.

Regeneron Pharmaceuticals presently has a consensus target price of $621.1481, suggesting a potential upside of 37.80%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Summary

Regeneron Pharmaceuticals beats Biogen on 9 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Alexion Pharmaceuticals and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Alexion Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alexion Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alexion Pharmaceuticals and Biogen, as provided by MarketBeat.

Alexion Pharmaceuticals presently has a consensus target price of $153.1250, suggesting a potential upside of 0.42%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Alexion Pharmaceuticals.

Summary

Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Seagen and Biogen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Seagen and Biogen, as provided by MarketBeat.

Seagen presently has a consensus target price of $188.4615, suggesting a potential upside of 24.89%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 11.51%. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Biogen.

Volatility and Risk

Seagen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings and Valuation

This table compares Seagen and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Biogen on 8 of the 15 factors compared between the two stocks.